Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

被引：0
|
作者：
Jun Guo
Yiran Huang
Xu Zhang
Fangjian Zhou
Yinghao Sun
Shukui Qin
Zhangqun Ye
Hui Wang
Annette Jappe
Patrick Straub
Nicoletta Pirotta
Sven Gogov
机构：
[1] Peking University Cancer Hospital and Institute,
[2] Shanghai Renji Hospital,undefined
[3] The General Hospital of PLA,undefined
[4] Sun Yat-sen University Cancer Center,undefined
[5] Shanghai Changhai Hospital,undefined
[6] Nanjing Bayi Hospital,undefined
[7] Wuhan Tongji Hospital,undefined
[8] Beijing Novartis Pharma Company,undefined
[9] Ltd.,undefined
[10] Novartis Pharma AG,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharma AG,undefined
[13] Novartis Pharma AG,undefined
来源：
BMC Cancer | / 13卷
关键词：
Asian; Everolimus; mTOR inhibitor; Renal cell cancer; Sunitinib; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study
    Kadono, Yoshifumi
    Konaka, Hiroyuki
    Izumi, Kouji
    Anai, Satoshi
    Fujimoto, Kiyohide
    Ishibashi, Kei
    Kawai, Noriyasu
    Kato, Taku
    Iba, Akinori
    Masumori, Naoya
    Yoshimura, Kenichi
    Mizokami, Atsushiu
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 15
  • [42] Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience
    Matrana, Marc R.
    Bathala, Tharakeswara
    Campbell, Matthew T.
    Duran, Cihan
    Shetty, Aditya
    Teegavarapu, Purnima
    Kalra, Sarathi
    Xiao, Lianchun
    Atkinson, Bradley
    Corn, Paul
    Jonasch, Eric
    Tannir, Nizar M.
    BJU INTERNATIONAL, 2016, 118 (02) : 264 - 271
  • [43] Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer
    Pant, Shubham
    Cho, Byoung Chul
    Kyriakopoulos, Christos E.
    Spira, Alexander
    Tannir, Nizar
    Werner, Theresa L.
    Yan, Xiaohong
    Neuteboom, Saskia
    Chao, Richard
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 547 - 558
  • [44] Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials
    Ghatalia, Pooja
    Je, Youjin
    Nguyen, Paul L.
    Quoc-Dien Trinh
    Choueiri, Toni K.
    Sonpavde, Guru
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (02) : 251 - 263
  • [45] Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors
    Eskens, Ferry A. L. M.
    Steeghs, Neeltje
    Verweij, Jaap
    Bloem, Johan L.
    Christensen, Olaf
    van Doorn, Leni
    Ouwerkerk, Jan
    de Jonge, Maja J. A.
    Nortier, Johan W. R.
    Kraetzschmar, Joern
    Rajagopalan, Prabhu
    Gelderblom, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4169 - 4176
  • [46] Sorafenib dose escalation in treatment-naive patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study
    Gore, Martin E.
    Jones, Robert J.
    Ravaud, Alain
    Kuczyk, Markus
    Demkow, Tomasz
    Bearz, Alessandra
    Shapiro, Joann
    Strauss, Uwe Phillip
    Porta, Camillo
    BJU INTERNATIONAL, 2017, 119 (06) : 846 - 853
  • [47] A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
    Ikeda, Masafumi
    Morimoto, Manabu
    Tajimi, Masaomi
    Inoue, Koichi
    Benhadji, Karim A.
    Lahn, Michael M. F.
    Sakai, Daisuke
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (01) : 118 - 126
  • [48] A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
    Masafumi Ikeda
    Manabu Morimoto
    Masaomi Tajimi
    Koichi Inoue
    Karim A. Benhadji
    Michael M. F. Lahn
    Daisuke Sakai
    Investigational New Drugs, 2019, 37 : 118 - 126
  • [49] Two Phase 2 Trials of the Novel Akt Inhibitor Perifosine in Patients With Advanced Renal Cell Carcinoma After Progression on Vascular Endothelial Growth Factor-Targeted Therapy
    Cho, Daniel C.
    Hutson, Thomas E.
    Samlowski, Wolfram
    Sportelli, Peter
    Somer, Brad
    Richards, Paul
    Sosman, Jeffrey A.
    Puzanov, Igor
    Michaelson, M. Dror
    Flaherty, Keith T.
    Figlin, Robert A.
    Vogelzang, Nicholas J.
    CANCER, 2012, 118 (24) : 6055 - 6062
  • [50] A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
    John D. Hainsworth
    James A. Reeves
    Joseph R. Mace
    Edward J. Crane
    Oday Hamid
    John R. Stille
    Amy Flynt
    Stephanie Roberson
    John Polzer
    Edward R. Arrowsmith
    Targeted Oncology, 2016, 11 : 643 - 653
12345